Oncolytics Biotech annual return on equity
2023
2024
Oncolytics Biotech Return on Equity (ROE) Growth & History (ONCY)
Oncolytics Biotech's return on equity was −199.07% for fiscal 2024.
View full Oncolytics Biotech company overviewOncolytics Biotech annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −199.07% | −92.14 pp |
| 2023 | 2023-12-31 | −106.92% | — |
Oncolytics Biotech quarterly return on equity
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −456.55% | — |
| Q2 2025 | 2025-06-30 | −117.43% | — |
| Q1 2025 | 2025-03-31 | −120.24% | — |
Oncolytics Biotech return on equity trends
Between the periods ended 2023-12-31 and 2024-12-31, Oncolytics Biotech's return on equity decreased from −106.92% to −199.07%, a change of −92.14 percentage points. The latest reported quarter, Q3 2025, shows −456.55%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oncolytics Biotech source filings ↗